ASH News Daily - Monday, December 12, 2011 - (Page B-33)

Monday, December 12, 2011 ASH NewS DAily Dr. Starczynowski developed an inmedical scientist. Dr. Starczynowski received his terest in blood-related cancers. Dr. Starczynowski’s PhD in molecular biolcommitment to studyogy from Boston Uniing hematologic maligversity. While studying nancies led him to join with Dr. Thomas Gilmthe lab of Aly Karsan, ore, Dr. Starczynowski MD, at the BC Cancer focused on the role of Research Center as a NF-κB in lymphomas. postdoctoral fellow and He identified mutations to investigate myeloin c-REL, one of the NFdysplastic syndromes κB subunits, from B-cell (MDS). One of his oblymphoma patients and jectives was to identify determined that these novel candidate genes in mutations may contribB:8.75 in MDS; however, instead ute to lymphoma develT:7.5 in opment. It was during Daniel T. Starczynowski, of searching for proteinS:6.75 in coding genes, he diverthis graduate studies that PhD Page B–33 ® career-development awardS Scholars «« From Page B-31 tional consultant for many of the athletic teams. Following a move back to his home state of California, he conducted research at the University of California at San Francisco, where he was a consultant for NASA and received an Achievement Award for his studies centered around the SLS2 Life Sciences Space Shuttle Mission. Dr. Murphy received his doctorate in molecular and cellular biology from Oxford University in the United Kingdom, where he was named the Mary Lundt Scholar in Biology. Returning to the United States, he then JOB#: 10561 murphy PROOF#: 1 conducted his postdoctoral studies CLIENT: Alexion in the laboratoryDisease Richard C. Mulliof Concept Jrnl Ad DESC: Color: 4C gan, PhD, at Harvard Medical School AD: NT and the TRAFFIC: CR OPERATOR: zv Children’s GALLEY#: 1 Hospital in DATE: 10/19/11 - 7:53 PMPM CREATED: 7/22/11 - 5:38 Boston, as FONTS: Trade Gothic LT Std Bold Trade Gothic a fellow in Condensed No. 20,Trade Gothic LT LT Std Bold No. 2, molecular Std Regular, Trade Gothic LT Std Condensed No. 18, Trade Gothic LT m e d i c i n e Std Condensed No. 18 Oblique responsible IMAGES: 10561C_journalAD_fn.tif, Alexion_KO.eps for the de- COLORS: C=0 M=100 Y=75 K=5 NOTES: sign, de- DOC PATH: Macintosh velopment, HD:Users:vazz:Desktop:10/19:ALX_ SLR_Q10561C_JA_D01:ALX_SLR_ and imple- Q10561C_JA_D01.indd DOC SIZE: 10.75” X 13.25” George J. mentation PRINT SCALE: 100% Murphy, PhD of stem cell and gene-based protocols aimed at combating hematopoietic, immunologic, and musculoskeletal disease. Recruited to Boston University as an independent researcher in 2010, Dr. Murphy now heads a laboratory composed of dynamic and passionate young researchers who utilize stem cell biology and regenerative medicine to combat blood-borne disease. Dr. Murphy has produced numerous peer-reviewed articles in high-profile journals such as Nature Medicine, Blood, the Journal of Clinical Investigation, and the Proceedings of the National Academy of Sciences. He regularly speaks at schools in the Boston metropolitan area and beyond in order to inspire today’s youth to consider a future career in the sciences. A wholehearted believer in the connection of the mind and body, he is an avid rock climber and natural bodybuilder. Cosmos Communications 718.482.1800 ed his attention to non-coding genes. In particular, Dr. Starczynowski has identified key miRNAs that are deleted in MDS patients and showed that loss of these miRNAs in mouse hematopoietic stem cells (HSC) results in a phenotype resembling human MDS. Following his postdoctoral training, Dr. Starczynowski joined the faculty at Cincinnati Children’s Hospital Medical Center and at the University of Cincinnati as an assistant professor. Dr. Starczynowski’s laboratory is continuing to investigate the molecular and cellular basis »» SCHOLARS Page B-34 n xio 29 Ale 8 it oth Vis bo at Daniel T. Starczynowski, PhD Dr. Starczynowski has always been interested in human diseases. However, it was not until a brief independent project as an undergraduate at Fairleigh Dickinson University that he acquired a passion for research. It was in this moment of clarity that Dr. Starczynowski decided to commit to a career as a bio- 20658a C M Y K CATaHUSTROPHIC In atypical Hemolytic Uremic Syndrome (aHUS), chronic uncontrolled complement activation causes systemic thrombotic microangiopathy (TMA), which can result in sudden and progressive vital organ failure and premature death1-5 Chronic uncontrolled complement activation causes the continuous activation of platelets and endothelial cells, leading to systemic TMA.3,6 Systemic, complement-mediated TMA can lead to sudden, fatal complications and progressive failure of vital organs, including the kidneys, heart, and brain.1-4,7 aHUS is a devastating and life-threatening disease of chronic uncontrolled complement activation.1,2,5 10.19.11 133 1 ej 2 Q1 Q2 To learn more about aHUS, please visit booth 829 and www.aHUSsource.com References: 1. Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2008;23:1957-1972. 2. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844-1859. 3. Fang CJ, Richards A, Liszewski MK, Kavanagh D, Atkinson JP. Advances in understanding of pathogenesis of aHUS and HELLP. Br J Haematol. 2008;143:336-348. 4. Sallée M, Daniel L, Piercecchi MD, et al. Myocardial infarction is a complication of factor H-associated atypical HUS. Nephrol Dial Transplant. 2010;25:2028-2032. 5. Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T. Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost. 2010;36:673-681. 6. Ståhl AL, Vaziri-Sani F, Heinen S, et al. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood. 2008;111:53075315. 7. Neuhaus TJ, Calonder S, Leumann EP. Heterogeneity of atypical haemolytic uraemic syndromes. Arch Dis Child. 1997;76:518-521. Copyright © 2011, Alexion Pharmaceuticals, Inc. All rights reserved. SOL 1172A 

Table of Contents for the Digital Edition of ASH News Daily - Monday, December 12, 2011

ASH News Daily - Monday, December 12, 2011

https://www.nxtbookmedia.com